Life Sciences

Life sciences companies face unique issues in accessing capital markets, including matters related to due diligence, public relations, regulatory and intellectual property. Goodwin offers a team of sophisticated life sciences lawyers who have expertise with these issues and extensive experience across the full breadth of equity and debt capital markets, advising issuers, sponsors, underwriters and investors in a variety of transactions to ensure deals close smoothly and in a timely way.

Pricing pressure, the reimbursement landscape, eroding margins, low valuations and the tax-friendly political climate are just a few of the factors positioning the life sciences industry for a ramp-up of M&A activity. The climate will be competitive for both buy and sell side prospects, and expert legal advice is critical for companies to be able to seize attractive, strategic opportunities. Thinking about M&A, even as a mere twinkle in your strategic plan? Goodwin can help.

Intellectual property protection is a crucial component for all life science companies. Our life sciences patent lawyers, patent agents and technical staff help assure that the best intellectual property strategy is in place to position and secure intellectual property protection, including patent protection, of our client’s core technology and lead therapeutic moieties, including small molecules, biologics, formulations, delivery systems, companion diagnostics, and medical devices. We have extensive experience in providing intellectual property diligence and assessment of patent landscapes to assist our clients, including operating companies, investors and financial institutions in connection with funding events, including public offerings and private financings, and to solidifying intellectual property positions for acquisition or other exit strategies.

In order to survive and thrive, emerging-growth biotech and specialty pharmaceutical companies depend on the ability to strategically develop, exploit and monetize their intellectual property and product portfolios. Goodwin’s licensing and partnering practice does just that. We offer unmatched counsel and a deep bench of talented lawyers located in biotech, medical and scientific innovation centers throughout the United States.

Companies regulated by the Food and Drug Administration (FDA) know that expertise and practical advice are critical to the bottom line. Goodwin’s experienced FDA practice, a key component of the firm’s Technology & Life Sciences team, provides strategic counseling and skillful advocacy to companies subject to the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, and related federal and state laws. 

Forming, operating and financing an emerging life sciences company can be challenging and time consuming. The experienced lawyers on Goodwin’s Life Sciences team can help guide you through these matters in addition to the varied legal issues that emerging life sciences companies face, allowing you to focus on your core business. With the breakneck pace of technology disrupting industries around the world, and in a highly competitive and fast-paced market, our team has unparalleled experience partnering with emerging life sciences companies ­– from formation through financing to an exit event. In just the last three years the Goodwin Life Sciences team has advised life science companies on over 170 life sciences equity financing deals alone. Our team takes the time to get to know and understand you and your business so that we can better advise you.

Litigation in the pharmaceutical and biotechnology industry can be particularly complex, requiring counsel that is as well versed across scientific disciplines as it is in the law. Goodwin has made servicing the needs of the pharmaceutical and biotechnology industries a strategic priority for more than two decades, and we have one of the largest and most active life sciences practices in the United States. Our IP litigation team is among the most experienced in the country, successfully representing both brand and generic companies in Hatch-Waxman litigation. Our portfolio of clients includes some of the largest innovator and generic companies in the world, and we have represented our clients in patent cases involving some of the world’s biggest blockbuster drugs.

Our firm is also a leader in the emerging field of biologics and biosimilars litigation. Our lawyers were involved in the legislative process that resulted in the Biologics Price Competition and Innovation Act (BPCIA), and our work counseling clients as they advance their biologic and biosimilar development programs has been a natural outgrowth of our extensive work on behalf of the pharmaceutical industry. Clients consistently praise our blog, BigMoleculeWatch.com, for its timely and relevant posts on biosimilar-related litigation, legislation and regulatory developments. In addition, our team authored Guide to Biosimilars Litigation and Regulation in the U.S., 2019-2020 ed., a first of its kind publication that explores the BPCIA.

As businesses today face an increasingly sophisticated threat environment compounded by aggressive regulatory enforcement, companies need a partner who can help mitigate risk and respond to the unthinkable. Our Legal 500 and Chambers ranked Privacy + Cybersecurity practice is one of the longest-standing of any AmLaw 50 firm. Dating back to the late 1990s and established formally in 2004, our practice is fully integrated and leverages the firm's core strengths, with the group's lawyers coming from our technology, financial institutions, licensing, litigation, regulatory and appellate practices. Our unique approach, focusing on client needs and value, enables us to engage specialists whose experience is framed by a holistic understanding of clients' greatest risks in this threatening environment.

Workouts. Reorganization. Liquidation.

Companies of all sizes – from start-ups to more established businesses and international corporations – have benefited over the last several years from sustained economic growth, favorable interest rates and higher investment income. Banner years have been common for many businesses. Yet the reality is that not every business succeeds. Shifting investor preferences, regulatory developments, ongoing disputes over tariffs and trade, and the potential for economic slowdown could mean trouble for many companies going forward.